AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.
Full Year 2024 Results Key Financial Results Revenue: US$56.3b (up 3.7% from FY 2023). Net ...
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
In this article, we are going to take a look at where AbbVie Inc. (NYSE ... increasingly looking for medicines in China. According to data from DealForma, as reported by CNBC, around 30% of ...
Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...
The rise of remote work is transforming real estate, driving demand for flexible workspaces, data centers, and suburban ...
California biotech Calibr and partner AbbVie have reported the first clinical data on a new CAR-T technology, which uses "switchable" cells that aim to eliminate the life-threatening side-effects ...
AbbVie has agreed a $200 million-plus takeover ... which has already generated encouraging phase 2b data in psoriasis. There's already stiff competition in the oral psoriasis category, however ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback